SELLAS Life Sciences (SLS) Accounts Payables (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Accounts Payables for 17 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 3.27% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (down 3.27% YoY), while the FY2025 annual figure was $2.9 million, down 15.77% from the prior year.
• Accounts Payables climbed to $3.6 million in Q1 2026 per SLS's latest filing, from $2.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $7.4 million in Q1 2024 and bottomed at $2.1 million in Q3 2022.
• Historically, Accounts Payables has averaged $3.9 million across 5 years, with a median of $3.5 million in 2024.
• Annual changes were most pronounced in 2024 — Accounts Payables surged 139.01% — and 2025, when it plunged 49.31%.
• SELLAS Life Sciences' Accounts Payables stood at $3.4 million in 2022, then jumped by 67.98% to $5.6 million in 2023, then slumped by 37.93% to $3.5 million in 2024, then fell by 15.77% to $2.9 million in 2025, then increased by 23.24% to $3.6 million in 2026.
• Business Quant data shows SLS's Accounts Payables at $3.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.3 million in Q3 2025.